|
[Related PubMed/MEDLINE]
Total Number of Papers: 48
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. |
ACR, BIM, csDMARD, DMARDs, JAK, NMA, NNT, RA |
| 2 |
2020 |
Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan. |
ACPA, RA |
| 3 |
2020 |
Biologic Agents Reduce Cardiovascular Events in Rheumatoid Arthritis Not Responsive to Tumour Necrosis Factor Inhibitors: A National Cohort Study. |
CI, CV, HR, MACE, RA |
| 4 |
2020 |
Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. |
axSpA, PS, SEC |
| 5 |
2020 |
Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. |
bDMARD, DAS28-CRP, RA |
| 6 |
2020 |
Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. |
bDMARDs, csDMARDs, LDA |
| 7 |
2020 |
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naive patients. |
OSMs, PDE4, PsA |
| 8 |
2020 |
Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. |
--- |
| 9 |
2020 |
Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study. |
AS, IRs, LTBI, PsA, PY, RA, SIRs, TB |
| 10 |
2020 |
Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. |
mSASSS |
| 11 |
2020 |
What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? |
ADAs, BP, RA, TDM |
| 12 |
2019 |
An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. |
ADA, GOL, IFX, PMPM, TOFA, UC, VEDO |
| 13 |
2019 |
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. |
DMARDs, JAK, RA |
| 14 |
2019 |
Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. |
CVD, LAR, RA, ROC, TCZ |
| 15 |
2019 |
Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. |
ACPAs, bDMARDs, CDAI, RA |
| 16 |
2019 |
Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis |
IL, PsO |
| 17 |
2019 |
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis. |
csDMARDs, ICER, MTX, RA |
| 18 |
2019 |
Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. |
PsA, TNFi |
| 19 |
2019 |
Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. |
ABT, AD, bDMARDs, CT, ILD, RA, TCZ |
| 20 |
2019 |
Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China. |
AS, BASFI, BASMI, CASPIC |
| 21 |
2019 |
Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naive Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. |
ACR, CI, HAQ, RA, RCTs |
| 22 |
2019 |
Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs. |
bDMARDs, CI, csDMARDs, DMARDs, HR, PS, RA, SIs |
| 23 |
2019 |
The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. |
AS, PsA, RA |
| 24 |
2019 |
Use of FDA-Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic. |
ACR, FDA, IL-17, IL-23, OSMs, PsA |
| 25 |
2019 |
Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. |
AS, CD, JIA, PsA, PsO, RA, UC |
| 26 |
2018 |
Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. |
AS, HR |
| 27 |
2018 |
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
bDMARDs, cDMARDs, ERG, HAQ-DI, ICERs, MTX, NHS, NICE, NMAs, QALY, RA, RTX, SAR, STA |
| 28 |
2018 |
The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. |
AAU, bDMARDs, SpA |
| 29 |
2018 |
The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study. |
--- |
| 30 |
2018 |
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. |
AS, ASDAS, mSASSS |
| 31 |
2018 |
Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry. |
AS |
| 32 |
2017 |
Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. |
PsA |
| 33 |
2017 |
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). |
bDMARDs, FACIT-F, HAQ-DI, MJS, PROs, PtGA, RA-BEACON |
| 34 |
2017 |
Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. |
ACR, EULAR, IMRDs, ISPOR, OLE, RCTs, s.c |
| 35 |
2016 |
Combination therapy with biologic agents in rheumatic diseases: current and future prospects. |
bDMARDs, csDMARDs, DMARDs, GCs, MTX, RA |
| 36 |
2016 |
Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. |
ACR20, NNT, PASI75, Ps, PsA |
| 37 |
2016 |
Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. |
cDMARDs, DMARD, HRQoL, PCS, RA, SF-36 |
| 38 |
2016 |
Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis? |
--- |
| 39 |
2016 |
Management of perioperative tumour necrosis factor alpha inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. |
ORs, SSIs |
| 40 |
2016 |
Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients. |
ABT, CI, LDA, OR, RA, ROC, TBCR |
| 41 |
2014 |
Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. |
cDMARDs, CI, DAS28, DMARDs, EQ-5D, HAQ, QALYs, RA, TACIT |
| 42 |
2014 |
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. |
ACS, CI, RA |
| 43 |
2014 |
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. |
CIs, PY, RA, REAL, REAL, SAEs, SIs |
| 44 |
2014 |
Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice. |
DMARDs, RA |
| 45 |
2012 |
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. |
ACR, AEs, DMARDs, IR, PY, RA |
| 46 |
2011 |
Brain-penetrating tumor necrosis factor decoy receptor in the mouse. |
BBB, mAb, TfR, TNFRs |
| 47 |
2010 |
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. |
ADA, AST, DMARDs, ETN, INF, LFT, MTX, ULN |
| 48 |
2007 |
Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. |
RA |
|
A Search Service for Abbreviation / Long Form
